Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Crescent Capital BDC: Weighing a Double-Digit Yield Against Financial Strain

Andreas Sommer by Andreas Sommer
December 7, 2025
in Analysis, Bonds, Dividends
0
Crescent Capital BDC Stock
0
SHARES
17
VIEWS
Share on FacebookShare on Twitter

For income-focused investors, Crescent Capital BDC presents a compelling proposition with a dividend yield exceeding 11%. However, this substantial payout comes with significant caveats, including an unsustainable distribution model and a steep share price decline over the past year.

Market analysts express cautious optimism regarding the stock’s price potential. The consensus average price target stands at $16.38, suggesting an approximate 10% upside from recent trading levels around $14.90. Sentiment among research firms is mixed: one issues a “Strong Buy” recommendation, three advocate “Buy,” one suggests “Hold,” and another advises “Sell.”

Assessing the Dividend’s Sustainability

The primary attraction of this investment is its high quarterly distribution of $0.42 per share. The upcoming ex-dividend date is set for December 31, 2025, with payment following on January 15, 2026.

A closer examination of the dividend’s foundation reveals considerable strain. The company’s payout ratio has ranged between 171% and 188%, indicating it is distributing far more capital to shareholders than it has earned in net income. Such a practice is widely viewed as untenable over the long term.

Should investors sell immediately? Or is it worth buying Crescent Capital BDC?

Financial Performance and Valuation Metrics

The equity has faced substantial headwinds, declining nearly 24% in value over the previous twelve months. Crescent Capital BDC currently commands a market capitalization of roughly $551 million.

Key valuation and balance sheet figures present a complex picture:
* The trailing twelve-month price-to-earnings (P/E) ratio is 15.3.
* The forward-looking P/E ratio is notably lower at 9.1.
* The debt-to-equity ratio, a measure of financial leverage, is reported at 1.2.

The firm’s most recent quarterly results, released in November, fell slightly short of market expectations. Earnings per share came in at $0.46 against a forecast of $0.47, while revenue reached $41.35 million versus an anticipated $42.35 million. Despite this minor earnings miss, management has maintained its current dividend policy.

Investors considering Crescent Capital BDC must carefully balance the allure of a high current income stream against the fundamental risks posed by its excessive payout ratio and negative price momentum. The next critical date for shareholders will be the year-end ex-dividend date.

Ad

Crescent Capital BDC Stock: Buy or Sell?! New Crescent Capital BDC Analysis from March 25 delivers the answer:

The latest Crescent Capital BDC figures speak for themselves: Urgent action needed for Crescent Capital BDC investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Crescent Capital BDC: Buy or sell? Read more here...

Tags: Crescent Capital BDC
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

Ocugen Stock
Analysis

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock
Analysis

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock
Bonds

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026
Next Post
Ryerson Stock

Ryerson's Strategic Acquisition: Navigating Risk Amid Expansion Plans

Lynas Stock

Lynas Secures Coveted Spot Among Australia's Top 50 Listed Companies

Solana Stock

France Emerges as a Key Market for Solana Amid Regional Divergence

Recommended

Target Stock

Target’s Survival Strategy Faces Market Skepticism Amid Steep Declines

4 months ago
Citizens Stock

Citizens Financial Group: A Study in Market Contradictions

7 months ago
Hims & Hers Health Registered (A) Stock

Hims & Hers Shares Face Critical Test Amid Growth Concerns

5 months ago
Uranium Energy Stock

Uranium Energy Stock Faces Dual Pressure from Geopolitics and Financials

2 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Realty Income’s Strategic Financing Defies High Interest Rate Environment

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

Battalion Oil Navigates Debt and Operational Overhaul

Divergent Analyst Views Highlight Coeur Mining’s Strategic Transition

Rocket Lab Stock Attracts Bullish Analyst Sentiment Amid Growth Trajectory

TSMC’s Arizona Expansion Gains Momentum Amid Record Retail Investor Interest

Trending

Take-Two Stock
Earnings

GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon

by SiterGedge
March 25, 2026
0

Take-Two Interactive has officially marked November 19, 2026, on the calendar as the release date for Grand...

Ocugen Stock

Ocugen Shares Slide Despite Positive Clinical Trial Results

March 25, 2026
ImmunityBio Stock

Regulatory Rebuke Sends ImmunityBio Shares Tumbling

March 25, 2026
Realty Income Stock

Realty Income’s Strategic Financing Defies High Interest Rate Environment

March 25, 2026
IBM Stock

IBM Shares Face Pressure from Analyst Downgrades and Acquisition Concerns

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • GTA VI Launch Date Sets Stage for Take-Two’s Financial Horizon
  • Ocugen Shares Slide Despite Positive Clinical Trial Results
  • Regulatory Rebuke Sends ImmunityBio Shares Tumbling

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com